News

April 21, 2017

The European Medicines Agency (EMA) Recommends Granting Marketing Authorization in the European Union for Spinraza

The European Medicines Agency (EMA) Recommends Granting Marketing Authorization in the European Union for Spinraza

The European Medicines Agency (EMA) has recommended granting a marketing authorization in the European Union (EU) for Spinraza. The recommendation indicates that Spinraza should be covered for all types of SMA.

This

READ MORE   |  

Topics: Front Page News

April 11, 2017

SMA Patient-Focused Drug Development Meeting with the FDA Set for Next Week

SMA Patient-Focused Drug Development Meeting with the FDA Set for Next Week

The SMA community is eagerly looking forward to next week’s Patient-Focused Drug Development (PFDD) Meeting with the FDA.

Over 400 members of the community are registered to participate in this event. This includes individuals and families affected by SMA, representatives from...

READ MORE   |  

Topics: Our Impact, Advocacy, Front Page News

April 10, 2017

Cure SMA Awards $75,000 Grant to Jean Giacomotto, PhD, University of Queensland, Australia

Cure SMA Awards $75,000 Grant to Jean Giacomotto, PhD, University of Queensland, Australia

Cure SMA has awarded a $75,000 research grant to Jean Giacomotto, PhD, at the University of Queensland, for his project, "Zebrafish models of Spinal Muscular Atrophy optimized for chemical genetics and drug discovery. From proof-of-principle to new insights and treatments".

In SMA, the...

READ MORE   |  

Topics: Research, Front Page News

Items 4 - 6 of 333  Previous12345678910Next

© 2014 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software